Trending News Today: Lilly's Migraine Drug Tops Competitors in New Prescriptions

Weekly US prescription data from IQVIA showed that Eli Lilly’s migraine drug galcanezumab-gnlm (Emgality) was the most prescribed therapy for first-time patients, Reuters reported. According to the article, galcanezumab-gnlm, which claimed 37.7% of first-time patients, won out against Amgen’s erenumab-aooe (Aimovig), whose share dropped to 37.2%, as well as Teva, who came in at a 25.1% share. Lilly is the only manufacturer in the class currently covered by all 3 of the leading pharmacy benefit managers: Cigna’s Express Scripts, UnitedHealth Group’s OptumRx, and CVS Health, the article reported.
 
Forty-four US states filed a lawsuit against 20 drug manufacturers, accusing the companies of inflating prices and working to stifle competition, The Hill reported. According to the article, the suit alleges that the drug companies illegally divided up the market to limit competition and coordinated to raise prices. The complaint also said that Teva allegedly conspired to increase prices of 86 drugs between July 2013 and January 2015, the article reported.
 
A recent study has identified a new target in the mitochondria of cancer cells that indicate the potential of a treatment class for certain blood cancers, The American Journal of Managed Care reported. According to the article, the target, caseinolytic protease P (ClpP) offers insight into how impiridones work by inducing cancer cell deaths in blood cancers such as acute myeloid leukemia. Overall, the findings support the clinical development of impiridones and other ClpP activators for human cancers, the article reported.



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$